Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Pay attention to this red flag

<< Previous

Bullboard Posts

Next >>

Comment by oldposty2on Jun 02, 2021 4:03pm

419 Views

Post# 33312652

RE:Pay attention to this red flag

There has been a short play on this since mid april, a large percentage of shareholders are users and bought in on the hopes of legalization, their being spooked and are panic selling.Why insiders are selling? Your guess is as good as anybodys. JMHO

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?